Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 2656814, 12 pages
http://dx.doi.org/10.1155/2016/2656814
Research Article

Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer

1Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV 26505, USA
2Healthcore, Inc., Wilmington, DE 19801, USA
3Department of Radiation Oncology, School of Medicine, West Virginia University, Morgantown, WV 26505, USA
4Evidera, Lexington, MA 02420, USA
5Sanofi U.S., Inc., Bridgewater, NJ 08807, USA

Received 5 December 2015; Accepted 9 May 2016

Academic Editor: Daniela Foti

Copyright © 2016 Amit D. Raval et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Giovannucci, D. M. Harlan, M. C. Archer et al., “Diabetes and cancer: a consensus report,” Diabetes Care, vol. 33, no. 7, pp. 1674–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Abdollah, A. Briganti, N. Suardi et al., “Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?” Prostate Cancer and Prostatic Diseases, vol. 14, no. 1, pp. 74–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Bansal, A. Bhansali, G. Kapil, K. Undela, and P. Tiwari, “Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies,” Prostate Cancer and Prostatic Diseases, vol. 16, no. 2, supplement 1, pp. 151–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kang, M.-H. Chen, Y. Zhang et al., “Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 82, no. 3, pp. e463–e467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Ribeiro, S. Pereira, S. Andrade et al., “Insulin prevents leptin inhibition of RM1 prostate cancer cell growth,” Pathology and Oncology Research, vol. 18, no. 2, pp. 499–507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Lubik, J. H. Gunter, S. C. Hendy et al., “Insulin increases de novo steroidogenesis in prostate cancer cells,” Cancer Research, vol. 71, no. 17, pp. 5754–5764, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Xu, H.-W. Jiang, G.-X. Ding et al., “Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis,” Diabetes Research and Clinical Practice, vol. 99, no. 3, pp. 241–249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Khera, D. Crawford, A. Morales, A. Salonia, and A. Morgentaler, “A new era of testosterone and prostate cancer: from physiology to clinical implications,” European Urology, vol. 65, no. 1, pp. 115–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Ashokkumar, L. Pari, and C. A. Rao, “Effect of N-benzoyl-D-phenylalanine and metformin on insulin receptors in neonatal streptozotocin-induced diabetic rats: studies on insulin binding to erythrocytes,” Archives of Physiology and Biochemistry, vol. 112, no. 3, pp. 174–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Hadad, S. Fleming, and A. M. Thompson, “Targeting AMPK: a new therapeutic opportunity in breast cancer,” Critical Reviews in Oncology/Hematology, vol. 67, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Huang, S. Wullschleger, N. Shpiro et al., “Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice,” Biochemical Journal, vol. 412, no. 2, pp. 211–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. L. Bitting and A. J. Armstrong, “Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer,” Endocrine-Related Cancer, vol. 20, no. 3, pp. R83–R99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Deng, Y. Yang, X. Tang et al., “Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis,” Diabetes/Metabolism Research and Reviews, vol. 31, no. 6, pp. 595–602, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. I. B. Sahra, K. Laurent, A. Loubat et al., “The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level,” Oncogene, vol. 27, no. 25, pp. 3576–3586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Margel, D. Urbach, L. L. Lipscombe et al., “Association between metformin use and risk of prostate cancer and its grade,” Journal of the National Cancer Institute, vol. 105, no. 15, pp. 1123–1131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Müller, E. Raum, D. Rothenbacher, C. Stegmaier, and H. Brenner, “Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values?” Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 5, pp. 1350–1356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence-SEER 18 Regs Public Use, Nov. 2012 Sub (2000–2010)—Linked to County Attributes—Total US, 1969–2011 Counties, National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, Bethesda, Md, USA, 2013.
  18. J. L. Warren, C. N. Klabunde, D. Schrag, P. B. Bach, and G. F. Riley, “Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population,” Medical Care, vol. 40, no. 8, supplement, pp. 3–18, 2002. View at Google Scholar · View at Scopus
  19. “SEER-Medicare: How the SEER & Medicare data are linked?” 2013, http://appliedresearch.cancer.gov/seermedicare/aboutdata/.
  20. “Number of SEER-Medicare Patients with Part D Enrollment by Calendar Year Diagnosis Years 1986–2007,” 2013, http://appliedresearch.cancer.gov/seermedicare/aboutdata/enrollees.html.
  21. I. Thompson, J. B. Thrasher, G. Aus et al., “Guideline for the management of clinically localized prostate cancer: 2007 update,” The Journal of Urology, vol. 177, no. 6, pp. 2106–2131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. M. Andersen, “Revisiting the behavioral model and access to medical care: does it matter?” Journal of Health and Social Behavior, vol. 36, no. 1, pp. 1–10, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. J. B. Yu, P. R. Soulos, J. Herrin et al., “Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity,” Journal of the National Cancer Institute, vol. 105, no. 1, pp. 25–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Y. Chang, J. P. Weiner, T. M. Richards, S. N. Bleich, and J. B. Segal, “Validating the adapted Diabetes Complications Severity Index in claims data,” The American Journal of Managed Care, vol. 18, no. 11, pp. 721–726, 2012. View at Google Scholar
  25. Area Resource File: Overview, 2014, http://ahrf.hrsa.gov/overview.htm.
  26. M. R. Sargen, O. J. Hoffstad, D. J. Wiebe, and D. J. Margolis, “Geographic variation in pharmacotherapy decisions for U.S. medicare enrollees with diabetes,” Journal of Diabetes and its Complications, vol. 26, no. 4, pp. 301–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. L. C. Trantham, M. E. Nielsen, L. R. Mobley, S. B. Wheeler, W. R. Carpenter, and A. K. Biddle, “Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy,” Cancer, vol. 119, no. 19, pp. 3523–3530, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus